# Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa

> **NCT03129646** · PHASE3 · COMPLETED · sponsor: **Drugs for Neglected Diseases** · enrollment: 439 (actual)

## Conditions studied

- Visceral Leishmaniasis

## Interventions

- **DRUG:** Miltefosine
- **DRUG:** Paromomycin
- **DRUG:** Sodium stibogluconate

## Key facts

- **NCT ID:** NCT03129646
- **Lead sponsor:** Drugs for Neglected Diseases
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-24
- **Primary completion:** 2020-12-11
- **Final completion:** 2020-12-11
- **Target enrollment:** 439 (ACTUAL)
- **Last updated:** 2024-02-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03129646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03129646, "Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03129646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*